Cargando…
Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
AIMS: Dapagliflozin is a sodium–glucose co‐transporter 2 inhibitor that has been developed as oral glucose lowering drug. The original dosefinding studies focused on optimal glycaemic effects. However, dapagliflozin also affects various cardiorenal risk markers and provides cardiorenal protection. T...
Autores principales: | Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576615/ https://www.ncbi.nlm.nih.gov/pubmed/32311110 http://dx.doi.org/10.1111/bcp.14318 |
Ejemplares similares
-
Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020) -
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023) -
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018) -
The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
por: Sridhar, Vikas S., et al.
Publicado: (2023) -
Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)